Proposed IRA Expansion Would Cripple Biopharma, Lead to Fewer Drugs: Report
The proposed expansion to the Inflation Reduction Act would substantially harm U.S. biopharma, triggering hundreds of thousands of job...
top of page
NEWS
Dec 22, 2023
Biden’s New Medicine Rules Have Pharmaceutical Companies Slow-Walking New Therapies
Pharmaceutical companies are delaying, or outright canceling, the development of new medicines following new drug rules signed into law...
Dec 14, 2023
CMS Must Obtain Clinician Input Today To Prevent Part D Access Barriers Tomorrow
The passage of last year’s Inflation Reduction Act (IRA) made major structural changes to the way Medicare covers and pays for...
Nov 21, 2023
Foot Locker, Teamsters Show Their Drug-Benefit Managers the Door
Employers and unions are getting fed up with the firms they have used for years to help control their spending on prescription...
Nov 2, 2023
How The IRA Could Delay Pharmaceutical Launches, Reduce Indications, And Chill Evidence Generation
Clinical development programs for new drugs include an array of research conducted both before and after a drug’s initial approval by the...
Oct 23, 2023
Pharma Industry Readies for Drug Pricing Lawsuit Second Wave
Major drug companies are likely to ratchet up a sprawling legal attack aimed at challenging the Biden administration’s Medicare drug...
Sep 18, 2023
Biotech lab-space demand falls sharply as industry’s ‘sugar high’ turns into a ‘reset’
Demand for new lab space has plummeted by more than half since the end of 2021, and life science vacancy rates are the highest they’ve...
Sep 5, 2023
AstraZeneca CEO Pascal Soriot proposes a novel fix to the drug pricing law’s alleged cancer problem
Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the...
Aug 28, 2023
HHS Drops First 10 Drugs for Medicare Drug Price Negotiation
The U.S. Department of Health and Human Services (HHS) on Tuesday announced the first 10 drugs covered under Medicare Part D to be...
Aug 28, 2023
Biden administration chooses first 10 drugs for Medicare price negotiations
WASHINGTON — Medicare can now negotiate lower prices for 10 common high-price drugs, cutting out-of-pocket costs for an estimated 9...
Aug 27, 2023
The Growth of Biosimilars Continues to Create Hope for Lower Drug Costs
Before a once-in-a-generation pandemic struck the globe, adalimumab (Humira; AbbVie) was the most profitable drug in the world...
Jul 27, 2023
Roche: Have Abandoned Some Trials Due to U.S. Drug Pricing Plans
By Reuters FRANKFURT (Reuters) -Roche said it had abandoned certain drug development projects or acquisitions under consideration...
Jul 5, 2023
Genentech CEO Alexander Hardy warns of 'unintended consequences' from the Inflation Reduction Act
It’s been almost one year since Congress and the Biden administration passed the Inflation Reduction Act (IRA), and so far leaders in the...
Jun 27, 2023
On conference circuit, biotechs lobby for their identity as new IRA drug pricing reforms take hold
The biotech industry split off into two conference camps in early June: Oncology researchers headed to Chicago for the American Society...
Jun 20, 2023
Biopharma Execs Weigh Controversial Move: Opting Out of Medicare to Escape Drug Price Negotiations
A panel hosted last week by JP Morgan and the industry group PhRMA further hinted at possible sweeping changes to the U.S. drug...
Jun 15, 2023
Inflation Reduction Act is destabilizing investment in drug innovation, execs say
The science is there, but not the capital to get certain drugs to market. That means choices are being made, one says. The Inflation...
Jun 13, 2023
IRA side effect: Pharma companies will increasingly skip Medicare altogether, Lilly CEO says
As the Centers for Medicare and Medicaid Services races to finalize guidance on how it will negotiate — or dictate, depending on if you...
Jun 4, 2023
Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO
CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in full force here, with plenaries and poster...
Jun 1, 2023
IRA forcing pharmas to leave cancer patients in the lurch, CEOs say
The IRA is leading pharmas to forego fast-to-patient development strategies in favor of getting onto the market first with the largest...
May 18, 2023
Novartis CEO: Some Cancer Drugs Dropped From Pipeline Because of Medicare Price Negotiations
Novartis has dropped some early-stage cancer drugs from its pipeline because Medicare’s new ability to negotiate certain drug prices will...
bottom of page